Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

BACKGROUND: Due to recent concerns about the toxicity of trastuzumab emtansine (T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-DM1 and stereotactic radiation. METHODS: This is a single institution series...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Matthew N., Walker, Chelsea, Thawani, Chetna, Naz, Afrin, Figura, Nicholas B., Kushchayev, Sergiy, Etame, Arnold, Yu, Hsiang-Hsuan Michael, Robinson, Timothy J., Liu, James, Vogelbaum, Michael A., Forsyth, Peter A., Czerniecki, Brian J., Soliman, Hatem H., Han, Hyo S., Ahmed, Kamran A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934378/
https://www.ncbi.nlm.nih.gov/pubmed/33663447
http://dx.doi.org/10.1186/s12885-021-07971-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934378/
https://www.ncbi.nlm.nih.gov/pubmed/33663447
http://dx.doi.org/10.1186/s12885-021-07971-w

Ejemplares similares